Hunter College of City University of New York
Trial Pipeline
A Palliative Care Model Impact on Knowledge and Attitudes
NCT06860932
Task Specific Training for Advanced Multiple Sclerosis
NCT06506929
Eccentric Exercise and Fatigue in Multiple Sclerosis
NCT06505421
Couples Motivational Interviewing to Reduce Drug Use and HIV Risk in Vulnerable Male Couples
NCT06307977
Effect of Cooling on Balance Performance in Multiple Sclerosis
NCT06094855
Expanding the Potential of Couples HIV Testing: Adjunct Modules to Reduce Drug Use Among Vulnerable Male Couples
NCT05000866
Gain and Loss Framed Text Messaging to Reduce Drinking Among Older Adults
NCT06126107
Effects of Therapeutic Mobile Game on Anxiety
NCT05240794
Prevention and Risk: Treatment With a New Emphasis on Relationships
NCT03396367
Intervention INC: Interactive Nutrition Comics for Urban Minority Youth
NCT03165474
Examining Community-based Effectiveness of a Substance Use and HIV Risk Reduction Intervention for Young Men of Color
NCT03488914
Improving HIV and Alcohol-Related Outcomes Among HIV+ Persons in Clinic Settings
NCT02390908
Risk Reduction Intervention for Vulnerable Young Adult Males
NCT01118416
Therapeutic Areas
What the Pipeline for Hunter College of City University of New York Shows
According to the ClinicalTrials.gov registry, Hunter College of City University of New York is linked to 67 US clinical trials across every stage of research activity. Of those, 59 studies are currently recruiting — about 88% of the sponsor's indexed portfolio — and 7 are already marked complete, representing roughly 10% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Hunter College of City University of New York reports 0 late-stage studies (Phase 3 and Phase 4 combined) and 0 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Hunter College of City University of New York is Substance Use with 4 linked trials, and 9 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.